Tuesday, July 30
Time: 7:00 - 8:30 a.m.
Location:McCormick Center MR#N231
Sponsored by Thermo Fisher Scientific
HIV drug Resistance (HIVDR) can emerge with use of antiretroviral (ARV) drug for HIV treatment and prevention. The increasing prevalence of drug-resistant HIV strains poses a serious threat to the progress made over the past decades in combating the HIV epidemic and can be attributed to various factors, including incomplete adherence to ARV drugs regimens, suboptimal drug availability, and transmission of drug-resistant HIV strains. The World Health Organization (WHO) estimates that approximately 10% of people initiating ARV treatment (ART) globally have drug resistant HIV strains. This workshop will bring forward the perspectives of key option leaders in the field of HIVDR to discuss the current state of drug resistance globally, use of HIV drug resistance testing for public health surveillance and clinical management of person living with HIV (PLWH), and new challenges related to detection and monitoring HIVDR.
Stephen Williams, PhD
Clinical Director, Thermo Fisher Scientific
Gert van Zyl, MD, PhD
Executive Head, Department of Pathology, Stellenbosch University and National Health Laboratory Service, Cape Town, South Africa
Rami Kantor, MD, PhD
Professor of Medicine in the Division of Infectious Diseases, Brown University, Providence, Rhode Island
Urvi Parikh, PhD
Associate Professor of Medicine, Associate Director, Virology Core Laboratory, University of Pittsburgh, Pittsburgh, Pennsylvania
Take advantage of advanced rates by July 26 to save BIG. Members save even more! Learn more and register today!
ADLM 2024 offers something for everyone in laboratory medicine, from Plenaries featuring world-renowned scientists to intimate Roundtables.